Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma

Conclusion: With acceptable efficacy and good tolerability, GemDOx might be a new therapeutic option for relapsed or refractory DLBCL and PTCL.

Source: Journal of Cancer - January 15, 2021 Category: Cancer & Oncology Authors: Qiu-Dan Shen, Li Wang, Hua-Yuan Zhu, Jin-Hua Liang, Yi Xia, Jia-Zhu Wu, Lei Fan, Jian-Yong Li, Wei Xu Tags: Research Paper Source Type: research